Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:NX1) ) has shared an announcement.
Nexalis Therapeutics has reached a key development milestone with the first patient screened in its Phase 2 trial of IRX-211 for breakthrough cancer pain, moving the program into controlled clinical evaluation in its intended patient population. The multicentre, randomised, double-blind, placebo-controlled cross-over study will enrol about 156 opioid-tolerant cancer patients, using an initial open-label titration phase to individualise dosing before a cross-over comparison of IRX-211 against placebo.
The trial is designed to assess efficacy, safety and patient-reported outcomes in a condition where existing opioid therapies often fail to provide sufficiently rapid relief, and where market demand is expected to expand significantly over the next decade. Successful results would not only validate IRX-211’s fast-acting inhaled approach for poorly controlled breakthrough cancer pain but also position Nexalis for value-driving clinical data and potential future partnering opportunities in the global cancer pain market.
More about InhaleRx Limited
Nexalis Therapeutics Ltd is an Australian clinical-stage biopharmaceutical company focused on oncology supportive care. Its lead candidate, IRX-211, is a proprietary inhaled therapy being developed to provide rapid, predictable and patient-controlled relief for breakthrough cancer pain in opioid-tolerant cancer patients, targeting a large and growing global cancer pain market.
Average Trading Volume: 214,969
Technical Sentiment Signal: Sell
Current Market Cap: A$4.81M
For detailed information about NX1 stock, go to TipRanks’ Stock Analysis page.